Tryngolza
·
- Prescription status not stated
- Heart, blood pressure and circulation
- Active substance
- Olezarsen
- Made by
- Swedish Orphan Biovitrum AB (publ)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Tryngolza is indicated as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
Details
| Made by | Swedish Orphan Biovitrum AB (publ) |
|---|---|
| Active substance | Olezarsen |
| Used in | Heart, blood pressure and circulation |
| Classification | C10AX · Heart, blood pressure and circulation |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2025-09-17 |
| Last updated by the regulator | 2025-12-03 |
| EMA product number | EMEA/H/C/006477 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).